

NeuTec Pharma plc

21 January 2002

Publication of Pathfinder AIM Admission Document

NeuTec Pharma plc (“NeuTec” or the “Company”), a biopharmaceutical company which focuses on developing a portfolio of antibody-based therapeutic products designed to treat life-threatening infections, has today published its Pathfinder Admission Document relating to its intention to seek admission to the Alternative Investment Market of the London Stock Exchange (“AIM”), previously announced on 7th January 2002.

NeuTec is developing a portfolio of antibody-based therapeutic products designed to treat life-threatening infections, particularly hospital-acquired infections, such as methicillin resistant *Staphylococcus aureus* (“MRSA”) and systemic candidiasis, an important and life-threatening form of yeast infection, which are increasingly resistant to conventional antibiotics.

NeuTec Pharma intends to seek admission to AIM by way of a placing of new ordinary shares with institutional investors to raise approximately £10 million net of expenses (the “Placing”). No existing shareholders are selling shares in the Placing such that the directors and the University of Manchester will retain significant equity holdings post-admission.

Hoare Govett Limited is acting as nominated adviser and broker to the Company.

- Ends -

For further information, please contact:

NeuTec Pharma plc via Hogarth Partnership (see below)
Professor James Burnie, Chief Executive

Hoare Govett Limited 020 7678 8000
Justin Jones
Andrew Chapman

Hogarth Partnership 020 7357 9477
John Olsen
James Longfield
Georgina Briscoe

Contd./ 2

The directors of NeuTec Pharma plc accept responsibility for the information contained in this announcement. The contents of this announcement have been approved by Hoare Govett Limited solely for the purposes of section 21 of the Financial Services and Markets Act 2000. Hoare Govett Limited, which is authorised in the United Kingdom under the Financial Services and Markets Act 2000, is acting for NeuTec Pharma plc and for no-one else in connection with the Placing and will not be responsible to anyone other than NeuTec Pharma plc for providing the protections afforded to clients of Hoare Govett Limited or for providing advice in relation to the Placing.

This announcement does not constitute, or form part of, an offer or any solicitation of an offer, for securities and any purchase of, or application for, securities. In particular, this announcement is not an offer of securities for sale in the United States, Canada, Australia or Japan. The securities of the Company are not being registered under the US Securities Act of 1933, as amended (the "Securities Act") or under the applicable securities laws of Canada, Australia or Japan and, subject to certain exceptions, may not be offered or sold in the United States (as such term is defined in Regulation S under the Securities Act), Canada, Australia or Japan. No money, securities or other consideration is being solicited by this announcement or the information it contains in any jurisdiction in which such offer is not authorised or to any person to whom it is unlawful to make such an offer or invitation, and if sent in response to this announcement or the information it contains will not be accepted.